Log inSign up
AAOIFI No. 21 screening

Is HCM halal?

HUTCHMED (China) Limited

Not halal

HUTCHMED (China) Limited did not pass AAOIFI screening. The failed check is shown below.

Checked: 13 October 2026

Exchange

NASDAQ

Price

14.05

Day

+0.79%

Market cap

$2.38B

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

What the company does

HUTCHMED (China/Hong Kong) develops cancer drugs: Fruzaqla (fruquintinib for colorectal cancer, sold globally with Takeda), surufatinib and savolitinib in China. Revenue comes from drug sales and partner payments.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $93.16M ÷ current market cap $2.38B = 3.9%

    3.9%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $1.37B ÷ current market cap $2.38B = 57.5%

    57.5%

    Fail

  • Non-compliant income / total revenue

    limit 5%

    Interest income $49.88M ÷ annual revenue $548.51M (2025) = 9.1%

    9.1%

    Fail

Figures from the company's filings (2025-12-31), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Drug Manufacturers - Specialty & Generic — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.